Top

Published in:

Open Access 01-07-2008 | Original Article

Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study

Authors: Takafumi Ueda, Norifumi Naka, Nobuhito Araki, Takeshi Ishii, Hiroyuki Tsuchiya, Hideki Yoshikawa, Kazuo Mochizuki, Tadao Tsuboyama, Junya Toguchida, Toshifumi Ozaki, Hiroaki Murata, Ikuo Kudawara, Kazuhiro Tanaka, Yukihide Iwamoto, Yasuo Yazawa, Kazuyoshi Kushida, Takanobu Otsuka, Keiji Sato

Published in: Journal of Orthopaedic Science | Issue 4/2008

Abstract

Background

The radiographic evaluation of the response to preoperative chemotherapy for bone and soft tissue sarcomas is based mostly on the change in primary tumor size before and after chemotherapy, as is done for many solid cancers. Its prognostic correlation, however, has hardly been validated.

Methods

We conducted a retrospective validation study of the Japanese Orthopaedic Association (JOA) radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas as a JOA Committee on Musculoskeletal Tumors cooperative study. A total of 125 consecutive patients with high-grade bone (n = 77) and soft tissue (n = 48) sarcomas treated with neoadjuvant chemotherapy and definitive surgery in 25 tertiary referral hospitals were selected for the study. We investigated the correlation between the tumor size-based radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas provided by the JOA Committee on Musculoskeletal Tumors (hereafter called the JOA criteria) and the patients’ overall survival using the Kaplan-Meier method and the log-rank test.

Results

The JOA criteria correlated relatively well with survival for malignant bone tumors (mostly comprising osteosarcoma and Ewing’s sarcoma) but not for soft tissue sarcomas, suggesting that the tumor size-based radiographic evaluation criteria for the response to preoperative chemotherapy in patients with soft tissue sarcomas is invalid.

Conclusions

The JOA criteria, based on the change in primary tumor size, is valid for malignant bone tumors but invalid for soft tissue sarcomas. Other new evaluation modalities of the response to preoperative chemotherapy using innovative functional imaging techniques are needed for soft tissue sarcomas.

Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997;79:411–415.CrossRefPubMed

Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452–2458.PubMed

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities and trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–790.CrossRefPubMed

Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818–1829.PubMed

Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694–701.CrossRefPubMed

Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group Cooperative Study. Cancer 2007;109:767–775.CrossRefPubMed

Committee on Musculoskeletal Tumors. General rules for clinical and pathological studies on malignant bone tumors. 3rd edn. Tokyo: Kanehara; 2000. p. 67–68 (in Japanese).

Committee on Musculoskeletal Tumors. General rules for clinical and pathological studies on malignant soft tissue tumors. 3rd edn. Tokyo: Kanehara; 2002. p. 84–85 (in Japanese).

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.CrossRefPubMed

10.

Huvos AG. Osteogenic sarcoma: pathologic assessment of preoperative (neoadjuvant) chemotherapy. In: Bone tumors: diagnosis, treatment, and prognosis. 2nd edn. Philadelphia: Saunders; 1991. p. 122–128.

11.

Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol 1993;11:1763–1769.PubMed

12.

Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998;80:1020–1033.CrossRefPubMed

13.

Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19:3203–3209.PubMed

14.

Menendez LR, Ahlmann ER, Savage K, Cluck M, Fedenko AN. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop 2006;455:219–224.

15.

Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120–1126.CrossRefPubMed

16.

Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031–1039.CrossRefPubMed

17.

Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res 2005;11:5223–5232.CrossRefPubMed

18.

Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409–414.CrossRefPubMed

19.

Moon L, McHugh K. Advances in paediatric tumour imaging. Arch Dis Child 2005;90:608–611.CrossRefPubMed

20.

Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245–3251.CrossRefPubMed

21.

Prasad SR, Saini S, Sumner JE, Hahn PF, Sahani D, Boland GW. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr 2003;27:380–384.CrossRefPubMed

22.

Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257–260.CrossRefPubMed

23.

Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005;7:307–311.CrossRefPubMed

24.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760–1764.CrossRefPubMed

25.

Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442–4445.CrossRefPubMed

26.

Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, et al. FDG-PET for evaluating musculoskeletal tumors: a review. J Orthop Sci 2003;8:435–441.CrossRefPubMed

27.

Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU 3rd, et al. [¹⁸F]fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828–8834.CrossRefPubMed

28.

Menendez LR, Fideler BM, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft tissue sarcoma: a study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg Am 1993;75:526–531.PubMed

29.

Goto Y, Ihara K, Kawauchi S, Ohi R, Sasaki K, Kawai S. Clinical significance of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci 2002;7:304–312.CrossRefPubMed

Title: Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study
Authors: Takafumi Ueda
Norifumi Naka
Nobuhito Araki
Takeshi Ishii
Hiroyuki Tsuchiya
Hideki Yoshikawa
Kazuo Mochizuki
Tadao Tsuboyama
Junya Toguchida
Toshifumi Ozaki
Hiroaki Murata
Ikuo Kudawara
Kazuhiro Tanaka
Yukihide Iwamoto
Yasuo Yazawa
Kazuyoshi Kushida
Takanobu Otsuka
Keiji Sato
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: Journal of Orthopaedic Science / Issue 4/2008
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-008-1235-5

At a glance: The STEP trials

Springer Medicine

Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

In vivo articular cartilage contact at the glenohumeral joint: preliminary report

Proximal tibiofibular synostosis with 49,XXXXY syndrome, a rare congenital bone anomaly

Arthroscopic stabilization for traumatic anterior dislocation of the shoulder: suture anchor fixation versus transglenoid technique

Upper tibia osteotomy: long term results — realignment analysis using OASIS computer software

Arthroscopic excision of synovial hemangioma of the hip joint

Mechanical environment of the supraspinatus tendon: three-dimensional finite element model analysis